Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products

Only company able to offer ultra-rapid, assembly-free production of sequences up to 600 bp at scale in sequence-perfect clonal DNA or faster sequence-verified linear dsDNA fragment formats 

EMERYVILLE, Calif. – July 30, 2024 – Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Ansa is the only company able to synthesize complete, contiguous DNA oligonucleotides as long as 600 bp without requiring assembly, delivering products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments.

The launch of the Ansa Clonal DNA and Ansa DNA Fragments follows the successful completion of the company’s early access program, which provided researchers worldwide with complex synthetic DNA sequences that were either previously impossible to produce or constrained by significant quality shortcomings and progress-limiting turnaround times. One team of researchers at the Innovative Genomics Institute (IGI) worked with Ansa to manufacture DNA sequences with complex features to advance research related to microbial gene transfer and communities. Founded by Nobel Prize winner and genome-engineering technology expert Jennifer A. Doudna, PhD, IGI is a joint effort between the Bay Area’s leading scientific research institutions, UC Berkeley and UC San Francisco, with affiliates at UC Davis, Lawrence Berkeley National Laboratory, Lawrence Livermore National Laboratory, Gladstone Institutes, and other institutions.

“As we develop technologies to achieve precision microbiome genetic engineering, we routinely rely on complex DNA sequences, such as highly repetitive microbial replicons and guide RNA arrays,” said Jaymin Patel, PhD, Postdoctoral Researcher at IGI and UC Berkeley. “Ansa was the only company that could deliver these complex sequences, allowing us to test microbial editing tools that were previously inaccessible.”

Ansa’s innovative enzymatic DNA synthesis approach eliminates the need for harsh chemicals and does not damage the molecule as it is synthesized, enabling the direct synthesis of much longer strands than is possible with legacy chemical DNA synthesis techniques. These long constructs allow Ansa’s platform to reliably manufacture complex DNA elements such as repeats, hairpins, strong secondary structures, homopolymers, and more. Customers are using the Ansa platform to gain access to the full range of sequences found in genomes, which will advance biological engineering and the development of new therapeutics and sustainable products.

“The DNA synthesis industry has conditioned customers to accept the disappointment of frequent order rejections, delayed or partial order shipments, or synthesis failures as an acceptable business practice. Ansa strives to become the trusted partner in DNA synthesis by reliably building and delivering the complex and challenging DNA sequences scientists need to advance their research,” said Jason T. Gammack, CEO of Ansa Biotechnologies. “With this product launch, we look forward to empowering more scientists with the ability to let their imaginations run free, which will drive the next wave of breakthroughs across healthcare, life science research, and other industries powered by synthetic DNA.”

Live Webinar

Ansa Biotechnologies is hosting a webinar to share recent application data and provide additional details about how Ansa Clonal DNA and Ansa DNA Fragments can help accelerate innovation.

Complex DNA Synthesis for Your Most Ambitious Projects

Presenters:  Jaymin Patel, UC Berkeley, and Eric Estrin, Ansa Biotechnologies

Date and time: August 6, 2024, 12:00 pm ET

Registration: ansabio.com/webinar

For more information on Ansa Clonal DNA and Ansa DNA Fragments, please visit ansabio.com/products.

About Ansa Biotechnologies

Ansa Biotechnologies enables customers to push the limits of their scientific projects by delivering DNA sequences that can be difficult or even impossible to manufacture with legacy synthesis methods. Ansa’s products are powered by the company’s proprietary synthesis technology, which enables ultra-rapid, assembly-free enzymatic production of complex DNA sequences. This novel approach is poised to accelerate innovation across healthcare, life science research, and other industries powered by synthetic DNA. Ansa is headquartered in Emeryville, CA. For more information, visit ansabio.com or follow us on X and LinkedIn.

Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.